Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 4, 2007

Planet Technologies to Take Over Antigen Laboratories for $10M

  • Planet Technologies plans to acquire Antigen Laboratories for $10 million, as long as it is able to procure the required financing. Planet estimates it will need an additional $10 million for transaction-related professional fees, paying off of debts, purchasing a building, and funding clinical trials, as well as other expenses related to the regulatory approval process.

    “The acquisition of Antigen's allergenic extract immunotherapy business complements our existing allergen avoidance business,” points out Planet's CEO and president, Ed Steube.

    Planet believes that Antigen will benefit from its existing wholly-owned subsidiary, Allergy Control Products, through cross merchandising between each company's physician relationships.

    Upon completion of the acquisition, Planet intends to commence a sublingual immunotherapy (SLIT) clinical development program. Currently Antigen's allergenic extracts for immunotherapy are administered by subcutaneous injections. Planet expects that an FDA-approved SLIT product will expand the U.S. market.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »